Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ILK | Q13418 | 7/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.50 |
| ▸ | SLC12A5 | Q9H2X9 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9722718 | 0.85 | CYP2D6 (0.67) | ILKALDH1A1KEAP1LMNASLC12A2 | |
| SCHEMBL2860319 | 0.84 | ILK (0.62) | ILKALDH1A1KEAP1LMNASLC12A2 | |
| SCHEMBL2869002 | 0.82 | PKM (0.58) | ILKALDH1A1LMNAGFERCA12 | |
| SCHEMBL28770666 | 0.75 | ALDH1A1 (0.58) | ILKALDH1A1KEAP1LMNASLC12A2 | |
| SCHEMBL2868935 | 0.75 | PTPN1 (0.55) | CYP2D6HTT | |
| SCHEMBL686421 | 0.74 | ILK (0.78) | ILK | |
| SCHEMBL14346138 | 0.73 | IDO1 (0.61) | ALDH1A1KEAP1LMNASLC12A2SLC12A5 | |
| SCHEMBL10791860 | 0.72 | ALDH1A1 (0.49) | ILKALDH1A1LMNAGFERCYP2D6 | |
| SCHEMBL38660104 | 0.72 | CYP19A1 (0.85) | ALDH1A1KEAP1LMNASLC12A2SLC12A5 | |
| SCHEMBL3681880 | 0.72 | CYP19A1 (0.85) | ALDH1A1KEAP1LMNASLC12A2SLC12A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723366-B2 | Azole compounds as malonyl-CoA decarboxylase inhibitors for treating metabolic diseases | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-05-25 | — | — | US | disclosed |
| US-7723366-B2 | Azole compounds as malonyl-CoA decarboxylase inhibitors for treating metabolic diseases | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-05-25 | — | — | US | disclosed |
| US-7723366-B2 | Azole compounds as malonyl-CoA decarboxylase inhibitors for treating metabolic diseases | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-05-25 | — | — | US | disclosed |
| EP-1379243-B1 | METHODS FOR TREATING METABOLIC DISEASES USING MALONYL-COA DECARBOXYLASE INHIBITORS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2009-09-09 | — | — | EP | disclosed |
| EP-1379243-B1 | METHODS FOR TREATING METABOLIC DISEASES USING MALONYL-COA DECARBOXYLASE INHIBITORS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2009-09-09 | — | — | EP | disclosed |
| US-20040082564-A1 | Methods for treating metabolic diseases using malonyl-coa decarboxylase inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1379243-A1 | METHODS FOR TREATING METABOLIC DISEASES USING MALONYL-COA DECARBOXYLASE INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002066034-A1 | METHODS FOR TREATING METABOLIC DISEASES USING MALONYL-COA DECARBOXYLASE INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082564-A1 | Methods for treating metabolic diseases using malonyl-coa decarboxylase inhibitors | ME1, ME3, ME2 | ILK 4863/4885ALDH1A1 120/4885KEAP1 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.